Abstract
Cerecor has signed a second licensing deal with Merck & Co., this time gaining global rights to Merck’s small molecule NMDA (N-methyl-D-aspartate) receptor subunit 2B (NR2B) antagonist MK-0657 (now CERC-301) for all human indications, including depression. MK-0657 was initially developed for the treatment of Parkinson’s disease, but failed to show efficacy for this indication in a Phase I study. Cerecor plans to initiate clinical trials of the drug candidate in patients with treatment-resistant depression. The deal comes a month after the company licensed global rights to Merck’s catechol-O-methyltransferase (COMT) inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
